Veliparib dihydrochloride
Cat. No.：YN280009
CAS No. ：912445-05-7
| 产品名称: | Veliparib dihydrochloride |
| CAS No.: | 912445-05-7 |
| Chemical Name: | 2-[(2R)-2-methyl-2-pyrrolidinyl]-1H-benzimidazole-7-carboxamide, dihydrochloride |
| Synonyms: | 维利帕尼二盐酸盐; ABT-888 dihydrochloride |
| 分子量: | 317.21 |
| 分子式: | C₁₃H₁₈Cl₂N₄O |
| SMILES: | O=C(C1=C2NC([C@@]3(NCCC3)C)=NC2=CC=C1)N.Cl.Cl |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Veliparib dihydrochloride是有效的PARP1和PARP2抑制剂，Ki分别为5.2 nM，2.9 nM。 |
| IC50和靶点: | [{name:"PARP-2:2.9 nM (Ki)"},{name: "PARP-1:5.2 nM (Ki)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Davar, D., Beumer, J.H., Hamieh, L., et al.Role of PARP inhibitors in cancer biology and therapyCurr. Med. Chem.19(23),3907-3921(2012)
Javle, M., and Curtin, N.J.The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapyTher. Adv. Med. Oncol.3(6),257-267(2011)
Donawho, C.K., Luo, Y., Penning, T.D., et al.ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor modelsClin. Cancer Res.13(9),2728-2737(2007)
Albert, J.M., Cao, C., Kim, K.W., et al.Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer modelsClin. Cancer Res.13(10),3033-3042(2007)
Liu, X., Luo, X., Shi, Y., et al.Poly (ADP-ribose) polymerase activity regulates apoptosis in HeLa cells after alkylating DNA damageCancer Biol. Ther.7(6),934-941(2008)
Shelton, J.W., Waxweiler, T.V., Landry, J., et al.In vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cellsInt. J. Radiat. Oncol. Biol. Phys.86(3),469-476(2013)
Shunkwiler, L., Ferris, G., and Kunos, C.Inhibition of poly(ADP-ribose) polymerase enhances radiochemosensitivity in cancers proficient in DNA double-strand break repairInt. J. Mol. Sci.14(2),3773-3785(2013)
